Search Results

Containing any of the words

Only of the type

Vitamin D status and Covid-19 in Saudi Settings: A randomized open-label study on the possible role of vitamin D on improving clinical outcomes Drug Clinical Trial

"A Phase III, Multicenter, Randomized, Open-Lable Clinical Trial Comparing the Efficacy and Safety of MK-0431 A (the Fixed-Dose Combination of Sitagliptin and Metformin) to That of Liraglutide in Patients With Type 2 Diabetes Mellitus" Drug Clinical Trial

A Phase III, Multicenter, Randomized, Open-Lable Clinical Trial Comparing the Efficacy and Safety of MK-0431 A (the Fixed-Dose Combination of Sitagliptin and Metformin) to That of Liraglutide in Patients With Type 2 Diabetes Mellitus Drug Clinical Trial

A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (pINN Sotorasib) for the Treatment of Subjects with Previously Treated Locally Advanced Unresectable/Metastatic NSCLC with KRAS p.G12C Mutation Drug Clinical Trial

A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum Drug Clinical Trial

A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants with Propionic Acidemia Drug Clinical Trial

"A PHASE 2/3, MULTICENTER, MULTINATIONAL,OPEN-LABEL STUDY TO EVALUATE THE EFFICACY ANDSAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUMCOFACTOR DEFICIENCY (MOCD) TYPE A" Drug Clinical Trial

Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Capocard tablets (25 mg captopril) Produced by Dar AlDawa / Jordan versus Capoten® tablets (25 mg captopril) Produced by SPIMACO / KSA, in healthy subjects under fasting condition. Drug Clinical Trial

The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency Drug Clinical Trial

The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency Drug Clinical Trial